First Defense®

Search documents
ImmuCell Embarks on CEO Succession Planning Process
GlobeNewswire News Room· 2025-06-25 12:00
PORTLAND, Maine, June 25, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has commenced a search for a successor in the position of President and CEO. "I turn 65 this fall and have told my fellow Directors that I would like to retire from full-time work by ear ...
ImmuCell(ICCC) - 2025 Q1 - Earnings Call Presentation
2025-05-14 21:24
Cautionary Note Regarding Forward-Looking Statements (Safe Harbor Statement): This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and will often include words such as "expects", "may", "anticipates", "aims", "intends", "would", "could", "should", "will", "plans", "believes", "estimates", "targets", ...
ImmuCell Hires Chief Financial Officer
Newsfilter· 2025-04-07 13:00
Core Viewpoint - ImmuCell Corporation has appointed Timothy C. Fiori as Chief Financial Officer, bringing significant experience to the company during a crucial phase of its development [1][2][3]. Company Overview - ImmuCell Corporation focuses on developing, manufacturing, and marketing products that enhance the health and productivity of dairy and beef cattle [4]. - The company offers First Defense®, which provides Immediate Immunity™ to newborn calves, and is nearing the completion of Re-Tain®, a treatment for subclinical mastitis in dairy cows that avoids traditional antibiotic restrictions [4]. Leadership Changes - Timothy C. Fiori has approximately 24 years of finance and commercial operating experience from IDEXX Laboratories [2]. - Fiori expressed enthusiasm about joining ImmuCell and contributing to the company's growth, highlighting the potential of its product portfolio [3]. - Michael F. Brigham, President and CEO, emphasized that Fiori's experience will be instrumental in improving financial systems and operational efficiencies [3].